Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies are
| Agency | National Institutes of Health |
|---|---|
| Status | Forecasted |
| Opportunity number | RFA-NS-26-030 |
| Posted date | 02/12/2026 |
| Estimated total funding | 6,000,000 |
| Expected number of awards | 3 |
| Who can apply | Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions). |
| Assistance Listing (CFDA) | 93.853 |
| Description | The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies are creating new opportunities to treat, prevent, and potentially modify the course of dementias; however, progress is limited by challenges in delivery, safety, manufacturability, and readiness for clinical testing. This program is intended to support projects across the translational pipeline, from optimization through IND development and early clinical evaluation, for genomic and biologic therapeutic candidates with compelling preclinical evidence. Eligible projects may inclu |
| Agency contact | nindsdonadrd@mail.nih.gov |
| Official listing | https://www.grants.gov/search-results-detail/361287 |